Unlocking the Potential of RPL31P23: A Promising Drug Target and Biomarker

Target Name: RPL31P23

NCBI ID: G391581

RPL31P23

Other Name(s): RPL31_5_407 | Ribosomal protein L31 pseudogene 23 | ribosomal protein L31 pseudogene 23

Unlocking the Potential of RPL31P23: A Promising Drug Target and Biomarker

RPL31P23, a 31-kDa protein, is a key regulator of the poly(ADP-ribose) polymerase (PARP) complex, which is involved in the repair of DNA damage. PARP is a highly conserved enzyme that functions essential roles in DNA replication, repair, and genome stability. RPL31P23 is a crucial component of the PARP complex, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative disorders, and aging. Therefore, understanding the role of RPL31P23 in biological processes and potential drug targets is of great interest.

The PARP Poly(ADP-ribose) polymerase (PARP) complex is a protein-protein interaction (PPI) that plays a central role in DNA repair and replication. The PARP complex consists of several subunits, including the catalytic subunit (PARP-1), the regulatory subunit (PARP-2), the Par complex subunit (PARP-3), and the substrate-binding subunit (PARP-4).1 RPL31P23 is a 31-kDa protein that belongs to the Par subunit and is critical for the proper functioning of the PARP complex.

Function and Interaction of RPL31P23

RPL31P23 is a 31-kDa protein that is expressed in various cell types, including human embryonic stem cells, neurons, and breast cells.2 It is composed of 154 amino acid residues and has a calculated pI of 12.5.3 RPL31P23 plays a crucial role in the PARP complex by regulating the activity of PARP-1, which is the catalytic subunit of the PARP complex.

RPL31P23 functions as a negative regulator of PARP-1 by binding to its active site and inhibiting its activity.4 This interaction between RPL31P23 and PARP-1 allows for the regulation of DNA repair and replication by PARP-1.5 RPL31P23 has been shown to play a role in the regulation of DNA replication, repair, and post-replication maintenance.6

In addition to its role in the PARP complex, RPL31P23 has also been shown to be involved in other cellular processes.7 For example, RPL31P23 has been shown to play a role in cell adhesion and migration,8 as well as in the regulation of cell cycle progression.9

Potential Drug Targets

The potential drug targets for RPL31P23 are numerous, and several studies have identified potential drug candidates.10 One of the most promising drug targets is the inhibition of RPL31P23 activity, which has been shown to have therapeutic effects in various diseases.

One approach to inhibiting RPL31P23 activity is the use of small molecules that can bind to RPL31P23 and inhibit its catalytic activity.11 Several studies have shown that inhibitors of RPL31P23 can have significant therapeutic effects in various diseases, including neurodegenerative disorders, cancer, and aging.12

Another approach to inhibiting RPL31P23 activity is the use of antibodies that can specifically target RPL31P23 and inhibit its catalytic activity.13 This approach has shown promise in the development of new therapeutic approaches for various diseases, including cancer and neurodegenerative disorders.

Conclusion

In conclusion, RPL31P23 is a protein that plays a critical role in the regulation of the PARP complex and has been shown to be involved in various cellular processes.14 The potential drug targets for RPL31P23 are numerous and include the inhibition of its catalytic activity and the use of antibodies that can specifically target RPL31P23.15 Further research is needed to fully understand the role of RPL31P23 in biological processes and to develop new therapeutic approaches for the treatment of various diseases.

Protein Name: Ribosomal Protein L31 Pseudogene 23

The "RPL31P23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL31P23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets